文献速递炎症性肠病

阿普斯特治疗活动性溃疡性结肠炎的随机试验

Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-01-08

这项双盲2期试验在14国61中心纳入活动性UC患者,随机接受阿普斯特30mg、40mg或安慰剂每日两次12周。继续治疗至52周,初始30mg组40.4%、40mg组32.7%维持临床缓解。

要点

  • 继续阿普斯特至52周,初始30mg组40.4%、40mg组32.7%维持临床缓解。

核心结论

  • 尽管2期试验主要终点未达到,但阿普斯特30mg或40mg组第12周临床和内镜特征及炎症标志物均有改善。
  • 继续阿普斯特治疗至52周,至多40%患者维持临床缓解。

研究设计与样本

  • 双盲2期试验,在14国61中心进行,筛查期2015年1月至2017年5月。
  • 纳入活动性UC≥3个月、未接受生物制剂或传统治疗失败/不耐受/禁忌的成人患者。
  • 随机分配至阿普斯特30mg(n=57)、40mg(n=55)或安慰剂(n=58)每日两次治疗12周,随后随机继续阿普斯特30或40mg每日两次额外40周。

主要发现

  • 30mg与40mg组临床缓解差异与内镜改善差异相关。
  • 两阿普斯特组Mayo评分组分(排便频率、直肠出血、医师总体评估)较基线改善相似。
  • 第12周前,30mg和40mg组高敏C反应蛋白和粪钙卫蛋白中位百分比下降大于安慰剂组。
  • 第52周临床缓解率:初始30mg组40.4%,初始40mg组32.7%。

关键数值与推荐

  • 主要终点为第12周临床缓解,定义为Mayo总分≤2且各分项≤1。
  • 最常见阿普斯特相关不良事件为头痛和恶心。

临床怎么用

  • 阿普斯特30mg每日两次可能作为活动性UC的口服治疗选择,需关注第12周临床缓解和内镜改善。
  • 40mg每日两次在第12周临床缓解未显著优于安慰剂,选择剂量时需权衡。
  • 治疗应答者可考虑长期维持,至52周部分患者维持临床缓解。

局限性

  • 2期试验主要终点未达到。
  • 样本量较小(30mg组57例、40mg组55例、安慰剂组58例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: New oral therapeutic agents are needed for patients with ulcerative colitis (UC) who are unresponsive or intolerant to conventional therapy. METHODS: We performed a double-blind, phase 2 trial of adults with active UC for 3 months or more who were naïve to biologic therapy or had been failed by, could not tolerate, or had contraindications to conventional therapies. The study was performed at 61 sites in 14 countries (screening from January 2015 through May 2017). Patients were randomly assigned to groups given apremilast 30 mg (n = 57), apremilast 40 mg (n = 55), or placebo (n = 58) twice daily for 12 weeks; patients were then randomly assigned to groups that received apremilast, 30 or 40 mg twice daily, for an additional 40 weeks. Endoscopies were performed and biopsies were collected during the screening phase, at week 12, and at week 52. Blood and fecal samples were also collected and analyzed throughout the study. The primary endpoint was clinical remission at week 12, defined as a total Mayo score of 2 or less, with no individual subscore above 1. RESULTS: Clinical remission was achieved at week 12 by 31.6% of patients in the 30 mg apremilast group and 12.1% of patients in the placebo group (P = .01). However, only 21.8% of patients in the 40 mg apremilast group achieved clinical remission at week 12 (P = .27 compared with placebo). Differences in clinical remission between the 30 mg and 40 mg apremilast groups were associated with differences in endoscopic improvement. Both apremilast groups had similar improvements from baseline in Mayo score components (stool frequency score, rectal bleeding score, physician's global assessment). The 30 mg and 40 mg apremilast groups had greater median percent reductions in C-reactive protein (measured by a high-sensitivity blood test) and fecal calprotectin through week 12 than the placebo group. At week 52, clinical remission was achieved by 40.4% of patients initially assigned to the apremilast 30 mg group and 32.7% of patients initially assigned to the apremilast 40 mg group. The most frequent apremilast-associated adverse events were headache and nausea. CONCLUSIONS: Although the primary endpoint of clinical remission was not met in this phase 2 trial, a greater proportion of patients with active UC who received apremilast (30 mg or 40 mg) had improvements in clinical and endoscopic features, and markers of inflammation, at 12 weeks. Clinical remission was maintained to week 52 in up to 40% of patients who continued apremilast until that time point. ClinicalTrials.gov no: NCT02289417.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Danese S, Neurath MF, Kopoń A, et al. Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020. PMID: 31926340. doi:10.1016/j.cgh.2019.12.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。